CEO — James Rolke: The filing discloses the approval of restricted stock awards (compensation) to the CEO and CFO, not a change in their employment status or a departure.

and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Material Modification To Rights Of Security Holders. The information set forth under Item 1.01, Item 5.03, and

Entry Into A Material Definitive Agreement. On July 10, 2026, the Board of Directors (the “Board”) of Revelation Biosciences, Inc. (the “Company”) adopted a stockholder rights plan and entered into a Rights Agreement (the “Rights Agreement”) with Continental Stock Transfer & Trust Co., as Rights Agent, and declared a dividend of one preferred share purchase right (a “Right”) for each outstanding share of the Company’s common stock, par value $0.001 per share (“Common Stock”), payable to stock…

Amended employment agreements for the CEO and CFO were entered into, with changes in severance benefits and other terms.

and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Material Modification to Rights of Security Holders. Under Nasdaq rules, a listed company may not issue shares at a price below market value in an amount exceeding 20% of its outstanding shares (the “Exchange Cap”) without stockholder approval. As previously reported, on January 26, 2026, the Company issued Class J Common Stock Warrants, which required the Company to obtain stockholder approval to satisfy the requirements of the Exchange Cap rule. On March 18, 2026, the Company held a Special…

and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Entry into a Material Definitive Agreement. On January 23, 2026, Revelation Biosciences, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with two holders (the “Holders”) of 8,544,999 (pre-reverse stock split of one-for-four effected on January 28, 2026) existing Class I Common Stock Warrants exercisable for an aggregate of 8,544,999 pre-split (2,136,251 post-split) shares of its common stock (collectively, the “Existing Warrants”), to exe…

Material Modification to Rights of Security Holders. To the extent required, the information included in

Unregistered Sales of Equity Securities. The Company issued the Class J Common Stock Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2) and Rule 506(b) of Regulation D promulgated thereunder and intends to issue the Class J Common Stock Warrants pursuant to the same exemption or pursuant to the exemption provided by Section 3(a)(9) of the Securities Act. The description of the Class J Common Stock Warrants under

Material Modification to Rights of Security Holders. Pursuant to the terms of the Class I Common Stock Warrants, the expiration date of such Warrants is five years from the date of stockholder approval of the reservation of shares to the extent that issuances under the Warrants may exceed 20% of the Company’s total outstanding shares, which could trigger the Exchange Cap, as described below. By virtue of the stockholder approval on December 3, 2025, the expiration date of such Warrants is now…

and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Entry into a Material Definitive Agreement. On September 10, 2025, Revelation Biosciences, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with certain holders (the “Holders”) of 13,065,000 existing Class H Common Stock Warrants exercisable for an aggregate of 4,355,000 shares of its common stock (collectively, the “Existing Warrants”), to exercise their warrants at an exercise price of $2.20 per share, in exchange for the Company’s agree…

Unregistered Sales of Equity Securities. The Company issued the Class I Common Stock Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2) and Rule 506(b) of Regulation D promulgated thereunder and intends to issue the Class I Common Stock Warrants pursuant to the same exemption or pursuant to the exemption provided by Section 3(a)(9) of the Securities Act. The description of the Class I Common Stock Warrants under

Material Modification to Rights of Security Holders. To the extent required, the information included in

and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Material Modification of Rights to Security Holders. To the extent required by

Material Modification to Rights of Security Holders. To the extent required, the information included in

Entry into a Material Definitive Agreement. On May 28, 2025, Revelation Biosciences, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) 675,000 shares of its common stock, par value $0.001 per share…

Director — George Tidmarsh, M.D., Ph.D.: Dr. George Tidmarsh resigned from the Board of Directors without any disagreements.

and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.

Material Modification of Rights to Security Holders. To the extent required by

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 3, 2025, Revelation Biosciences, Inc. (the “Company”) received a decision letter issued by the Nasdaq Hearings Panel granting the Company’s request to continue its listing on The Nasdaq Stock Market, subject to effecting a reverse stock split by January 31, 2025 and its stock trading at or above $1.00 for at least ten consecutive trading days by February 14, 2025. The Company intend…